Owkin is a healthcare technology company building an autonomous AI Scientist to connect research with patient care and automate aspects of biopharmaceutical research and development. Its AI is designed to explore biological complexity, formulate hypotheses, and generate insights to support clinical research and industry decisions. The company’s K Pro platform is an AI agent that helps inform decisions across biopharma R&D, including clinical trial, patient and population, and early portfolio decisions. It also offers K Pro reports and tools for investigating biology and potential molecules.

Owkin says its AI is trained and validated using multimodal patient data, with findings explored through wet-lab infrastructure and refined with input from oncologists and biologists. The company also provides data access and works with data partners, alongside services and capabilities for patient and laboratory validation. Its wider ecosystem includes affiliated and incubated organisations focused on precision diagnostics and biological foundation models. Through products, research, publications, and partnerships, Owkin aims to advance AI-enabled discovery and support the translation of research into care.